je.st
news
Tag: merck
Merck Announces Full-Year and Fourth-Quarter 2012 Financial Results
2013-02-01 13:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. 2012 Full-Year Non-GAAP EPS of $3.82, Excluding Certain Items; GAAP EPS of $2.16; Fourth-Quarter Non-GAAP EPS of $0.83, Excluding Certain Items; GAAP EPS of $0.46 2012 Full-Year Worldwide Sales Were $47.3 Billion, a Decrease of 2 Percent, Including a 3 Percent Unfavorable Impact from Foreign Exchange; Fourth-Quarter Worldwide Sales Were $11.7 Billion, a Decline of 5 Percent, Including a 2 Percent Unfavorable Impact from Foreign Exchange Full-Year and Fourth-Quarter Double-Digit Global Sales Growth for JANUVIA, JANUMET, GARDASIL, VICTRELIS and ZOSTAVAX Offset the Decline in SINGULAIR Sales Following Patent Expiry in the United States Provides Update on Odanacatib Program; Now Anticipates Filing in 2014 2013 Full-Year Non-GAAP EPS Target of $3.60 to $3.70, Excluding Certain Items; GAAP EPS Range of $2.03 to $2.26 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012. Language: English Contact HTML: MerckMedia Contacts:Ron Rogers, 908-423-6449Steve Cragle, 908-423-3461orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
FDA OKs Merck OTC version of overactive bladder drug
2013-01-26 07:43:40| Biotech - Topix.net
Health regulators approved Merck & Co's nonprescription version of Oxytrol to treat overactive bladder in women ages 18 and older, the agency said on Friday.
Merck steers doctors away from HDL cholesterol drug
2013-01-11 18:06:36| Biotech - Topix.net
U.S. drugmaker Merck & Co said it is taking steps to suspend availability of its drug Tredaptive after the medicine, used to raise "good" HDL cholesterol, failed to prevent heart problems in a large study.
Tags: drug
doctors
cholesterol
hdl
Merck Provides Update on Next Steps for TREDAPTIVE (extended-release niacin/laropiprant)
2013-01-11 13:39:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the company is taking steps to suspend the availability of TREDAPTIVE (extended-release niacin/laropiprant) tablets worldwide. TREDAPTIVE is not approved for use in the United States. Language: English Contact HTML: MerckMedia:Pamela Eisele, 908-423-5042orSkip Irvine, 267-305-5397orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: update
steps
merck
extendedrelease
Merck Announces FDA Acceptance of Resubmission of New Drug Application for Sugammadex Sodium Injection
2013-01-07 14:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the resubmission of the New Drug Application (NDA) for sugammadex sodium injection has been accepted for review by the U.S. Food and Drug Administration (FDA). Merck expects the FDAs review to be completed in the first half of 2013. Language: English Contact HTML: MerckMedia Contacts:Pam Eisele, 908-423-5042Lainie Keller, 908-423-4187orInvestor Contact:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: application
drug
acceptance
injection
Sites : [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] next »